Total Payments
$5,643
2021 Payments
$49.94
Companies
18
Transactions
92
Medicare Patients
2,395
Medicare Billing
$262,292
Payment Breakdown by Category
Food & Beverage$5,612 (99.5%)
Consulting$15.80 (0.3%)
Education$14.74 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,612 | 90 | 99.5% |
| Consulting Fee | $15.80 | 1 | 0.3% |
| Education | $14.74 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ironwood Pharmaceuticals, Inc | $3,481 | 7 | $0 (2019) |
| Allergan Inc. | $470.61 | 16 | $0 (2019) |
| AbbVie Inc. | $448.86 | 16 | $0 (2020) |
| Gilead Sciences, Inc. | $283.82 | 4 | $0 (2019) |
| Prometheus Laboratories Inc. | $233.26 | 10 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $147.19 | 7 | $0 (2019) |
| PFIZER INC. | $138.54 | 7 | $0 (2019) |
| Janssen Biotech, Inc. | $123.14 | 6 | $0 (2019) |
| Takeda Pharmaceuticals America, Inc. | $67.12 | 5 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $57.22 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $49.94 | 3 | Alnylam Pharmaceuticals Inc. ($17.68) |
| 2020 | $41.36 | 3 | AbbVie Inc. ($23.23) |
| 2019 | $543.59 | 19 | AbbVie, Inc. ($155.41) |
| 2018 | $4,013 | 34 | Ironwood Pharmaceuticals, Inc ($3,398) |
| 2017 | $995.19 | 33 | Allergan Inc. ($302.08) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/08/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.81 | General |
| Category: Neuroscience | ||||||
| 03/16/2021 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Genetic Disease | ||||||
| 01/05/2021 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Antibiotic | ||||||
| 12/17/2020 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $11.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/29/2020 | Ferring Pharmaceuticals Inc. | CIMZIA (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/09/2020 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2019 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/02/2019 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/24/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $107.44 | General |
| Category: Virology | ||||||
| 06/25/2019 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/14/2019 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HBV | ||||||
| 06/11/2019 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/05/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $3.15 | General |
| Category: Immunology | ||||||
| 06/04/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Immunology | ||||||
| 05/24/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/08/2019 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 04/30/2019 | Janssen Biotech, Inc. | STELARA (Biological), SIMPONI | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Immunology | ||||||
| 04/16/2019 | Allergan Inc. | LASTACAFT (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/05/2019 | Janssen Biotech, Inc. | STELARA (Biological), SIMPONI | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Immunology | ||||||
| 02/19/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Immunology | ||||||
| 02/13/2019 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/05/2019 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/15/2019 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | In-kind items and services | $15.80 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 01/09/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/08/2019 | Ironwood Pharmaceuticals, Inc | Linzess (Drug), Viberzi | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 272 | 282 | $108,303 | $27,140 |
| 2022 | 10 | 681 | 702 | $293,147 | $74,791 |
| 2021 | 12 | 759 | 787 | $345,066 | $87,362 |
| 2020 | 12 | 683 | 706 | $291,304 | $72,999 |
Total Patients
2,395
Total Services
2,477
Medicare Billing
$262,292
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 118 | 127 | $34,036 | $8,551 | 25.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 45 | 45 | $25,695 | $5,666 | 22.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 15 | 16 | $11,536 | $3,641 | 31.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 17 | 17 | $8,925 | $3,335 | 37.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 41 | 41 | $16,195 | $3,316 | 20.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $11,916 | $2,630 | 22.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 111 | 112 | $64,848 | $14,233 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 156 | 168 | $45,360 | $11,519 | 25.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 132 | 132 | $43,824 | $10,365 | 23.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 45 | 46 | $33,764 | $10,074 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 82 | $31,160 | $7,654 | 24.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 82 | 88 | $35,200 | $7,546 | 21.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 35 | 35 | $18,655 | $6,978 | 37.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 17 | 17 | $9,061 | $3,407 | 37.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $5,863 | $1,753 | 29.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $5,412 | $1,263 | 23.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 110 | 113 | $67,644 | $14,627 | 21.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 123 | 127 | $50,050 | $12,050 | 24.1% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 46 | 47 | $35,579 | $10,435 | 29.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 110 | 110 | $37,532 | $9,901 | 26.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 119 | 130 | $36,219 | $9,887 | 27.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 57 | 57 | $28,866 | $7,259 | 25.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 90 | 92 | $38,059 | $6,997 | 18.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 30 | 30 | $16,548 | $5,976 | 36.1% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 27 | 27 | $14,931 | $4,139 | 27.7% |
About Dr. Mark Takemura, MD
Dr. Mark Takemura, MD is a Gastroenterology healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487721189.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Takemura, MD has received a total of $5,643 in payments from pharmaceutical and medical device companies, with $49.94 received in 2021. These payments were reported across 92 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($5,612).
As a Medicare-enrolled provider, Takemura has provided services to 2,395 Medicare beneficiaries, totaling 2,477 services with total Medicare billing of $262,292. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Torrance, CA
- Active Since 11/29/2006
- Last Updated 04/20/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1487721189
Products in Payments
- LINZESS (Drug) $3,588
- VIBERZI (Drug) $336.99
- Humira (Biological) $299.44
- Vemlidy (Drug) $245.09
- Mavyret (Drug) $126.19
- STELARA (Biological) $123.14
- XELJANZ (Drug) $70.37
- XIFAXAN (Drug) $70.12
- INFLECTRA (Biological) $68.17
- UCERIS (Drug) $67.51
- Amitiza (Drug) $58.97
- XIFAXANIBSD (Drug) $56.32
- Entyvio (Biological) $44.08
- OCALIVA (Drug) $38.96
- GATTEX (Drug) $23.75
- Linzess (Drug) $23.00
- Dexilant (Drug) $21.29
- CIMZIA (Drug) $18.13
- GIVLAARI (Drug) $17.68
- ZEPOSIA (Drug) $16.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Torrance
Dr. Tonny Lee, M.d, M.D
Gastroenterology — Payments: $133,902
Gastroenterology $133,902
Sara Kranke
Gastroenterology — Payments: $75,421
Gastroenterology $75,421
Dr. Jennifer Kolb, Md, MD
Gastroenterology — Payments: $60,794
Gastroenterology $60,794
Dr. Jerome Cohen, M.d, M.D
Gastroenterology — Payments: $38,553
Gastroenterology $38,553
Dr. Edward Piken, M.d, M.D
Gastroenterology — Payments: $23,781
Gastroenterology $23,781
Viktor Eysselein, M.d, M.D
Gastroenterology — Payments: $13,509
Gastroenterology $13,509